

Mikhail Ovanesov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8382357/publications.pdf>

Version: 2024-02-01

61
papers

1,744
citations

304743

22
h-index

276875

41
g-index

62
all docs

62
docs citations

62
times ranked

2089
citing authors

#	ARTICLE	IF	CITATIONS
1	Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. <i>Molecular Psychiatry</i> , 2008, 13, 173-186.	7.9	312
2	Spatial Propagation and Localization of Blood Coagulation Are Regulated by Intrinsic and Protein C Pathways, Respectively. <i>Biophysical Journal</i> , 2006, 90, 1489-1500.	0.5	126
3	Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1023-1027.	3.3	91
4	Initiation and propagation of coagulation from tissue factor-bearing cell monolayers to plasma: initiator cells do not regulate spatial growth rate. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 321-331.	3.8	88
5	Thrombin Activity Propagates in Space During Blood Coagulation as an Excitation Wave. <i>Biophysical Journal</i> , 2012, 103, 2233-2240.	0.5	79
6	Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. <i>Transfusion</i> , 2012, 52, 2113-2121.	1.6	77
7	Inhibitors in hemophilia A. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 109-124.	1.0	75
8	Hemophilia A and B are associated with abnormal spatial dynamics of clot growth. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2002, 1572, 45-57.	2.4	63
9	Enlargement of the lateral ventricles in mutant DISC1 transgenic mice. <i>Molecular Psychiatry</i> , 2008, 13, 115-115.	7.9	60
10	Epidemiology of venous thromboembolism (<scp>VTE</scp>) associated with pregnancy. <i>Birth Defects Research Part C: Embryo Today Reviews</i> , 2015, 105, 167-184.	3.6	57
11	Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. <i>Blood</i> , 2012, 120, 891-899.	1.4	50
12	Characterization of procoagulant extracellular vesicles and platelet membrane disintegration in DMSO-cryopreserved platelets. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 30422.	12.2	49
13	Astrocytes play a key role in activation of microglia by persistent Borna disease virus infection. <i>Journal of Neuroinflammation</i> , 2008, 5, 50.	7.2	46
14	Task-Oriented Modular Decomposition of Biological Networks: Trigger Mechanism in Blood Coagulation. <i>Biophysical Journal</i> , 2010, 98, 1751-1761.	0.5	44
15	Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011. <i>American Journal of Hematology</i> , 2013, 88, 1035-1040.	4.1	38
16	Dissecting the biochemical architecture and morphological release pathways of the human platelet extracellular vesiculome. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 3781-3801.	5.4	38
17	PC12 cell model of inducible expression of mutant DISC1: New evidence for a dominant-negative mechanism of abnormal neuronal differentiation. <i>Neuroscience Research</i> , 2007, 58, 234-244.	1.9	33
18	Effect of factor VIII on tissue factor-initiated spatial clot growth. <i>Thrombosis and Haemostasis</i> , 2003, 89, 235-242.	3.4	28

#	ARTICLE	IF	CITATIONS
19	Immunotherapy with CpG Oligonucleotides and Antibodies to TNF- α Rescues Neonatal Mice from Lethal Arenavirus-Induced Meningoencephalitis. <i>Journal of Immunology</i> , 2008, 180, 8231-8240.	0.8	28
20	Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 743-755.	1.0	28
21	Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012. <i>Transfusion</i> , 2014, 54, 2553-2565.	1.6	24
22	Clotting factor product administration and same-day occurrence of thrombotic events, as recorded in a large healthcare database during 2008-2013. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2168-2179.	3.8	24
23	Activation of Microglia by Borna Disease Virus Infection: In Vitro Study. <i>Journal of Virology</i> , 2006, 80, 12141-12148.	3.4	21
24	Expression and characterization of a codon-optimized blood coagulation factor VIII. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 709-720.	3.8	21
25	Spatial Dynamics of Contact-Activated Fibrin Clot Formation in vitro and in silico in Haemophilia B: Effects of Severity and Apheresis Treatment. <i>Mathematical Modelling of Natural Phenomena</i> , 2006, 1, 124-137.	2.4	20
26	Neonatal Borna disease virus infection in rats is associated with increased extracellular levels of glutamate and neurodegeneration in the striatum. <i>Journal of NeuroVirology</i> , 2007, 13, 185-194.	2.1	20
27	Persistent Borna Disease Virus (BDV) infection activates microglia prior to a detectable loss of granule cells in the hippocampus. <i>Journal of Neuroinflammation</i> , 2008, 5, 16.	7.2	19
28	Correction of microplate location effects improves performance of the thrombin generation test. <i>Thrombosis Journal</i> , 2013, 11, 12.	2.1	19
29	Determining the impact of instrument variation and automated software algorithms on the TGT in hemophilia and normalized plasma. <i>Thrombosis Research</i> , 2013, 132, 374-380.	1.7	19
30	Optimization of the thrombin generation test components to measure potency of factor VIII concentrates. <i>Haemophilia</i> , 2016, 22, 780-789.	2.1	14
31	Insect cell-based expression and characterization of a single-chain variable antibody fragment directed against blood coagulation factor VIII. <i>Protein Expression and Purification</i> , 2013, 88, 201-206.	1.3	13
32	Synergy Between Tissue Factor and Exogenous Factor XIa in Initiating Coagulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2334-2345.	2.4	13
33	Cluster III of Low-Density Lipoprotein Receptor-Related Protein 1 Binds Activated Blood Coagulation Factor VIII. <i>Biochemistry</i> , 2015, 54, 481-489.	2.5	10
34	Predicting dosing advantages of factor VIIa variants with altered tissue factor-dependent and lipid-dependent activities. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1302-1312.	3.8	9
35	Interconnectedness of global hemostasis assay parameters in simultaneously evaluated thrombin generation, fibrin generation and clot lysis in normal plasma. <i>Thrombosis Research</i> , 2016, 140, 132-139.	1.7	9
36	Association of immune globulin intravenous and thromboembolic adverse events. <i>American Journal of Hematology</i> , 2017, 92, E44-E45.	4.1	9

#	ARTICLE	IF	CITATIONS
37	Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue. Blood Advances, 2019, 3, 2668-2678.	5.2	7
38	Genetic contributions to influenza virus attenuation in the rat brain. Journal of NeuroVirology, 2008, 14, 136-142.	2.1	6
39	The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood: comment. Journal of Thrombosis and Haemostasis, 2015, 13, 1527-1530.	3.8	6
40	Can the diagnostic reliability of the thrombin generation test as a global haemostasis assay be improved? The impact of calcium chloride concentration. Haemophilia, 2017, 23, 466-475.	2.1	6
41	Comparative Analysis of Thrombin Calibration Algorithms and Correction for Thrombin- β 2macroglobulin Activity. Journal of Clinical Medicine, 2020, 9, 3077.	2.4	6
42	Effect of factor VIII on tissue factor-initiated spatial clot growth. Thrombosis and Haemostasis, 2003, 89, 235-42.	3.4	5
43	Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products. Journal of Thrombosis and Haemostasis, 2021, 19, 954-966.	3.8	4
44	Considerations on activity assay discrepancies in factor VIII and factor IX products. Journal of Thrombosis and Haemostasis, 2021, 19, 2102-2111.	3.8	4
45	Structural, functional, and immunogenicity implications of <i>F9</i> gene recoding. Blood Advances, 2022, 6, 3932-3944.	5.2	4
46	Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products. Biologicals, 2020, 67, 88-93.	1.4	3
47	Effect of pH on thrombin activity measured by calibrated automated thrombinography. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 944-945.	2.3	3
48	Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice. Thrombosis Journal, 2020, 18, 32.	2.1	3
49	Thrombin generation assay—modifications needed for its application to monitoring of replacement therapy for haemophilia. Haemophilia, 2021, 27, e129-e132.	2.1	3
50	Fluorescence artifact correction in the thrombin generation assay: Necessity for correction algorithms in procoagulant samples. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 447-455.	2.3	3
51	Thrombin generation test based on a 96-channel pipettor for evaluation of FXIa procoagulant activity in pharmaceuticals. Nature Protocols, 2021, 16, 3981-4003.	12.0	3
52	Development of a Continuous Thrombin Generation-Based Test to Measure Potency in Factor VIII Concentrates. Blood, 2011, 118, 1206-1206.	1.4	3
53	Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 211-222.	2.3	1
54	Evidence that the primary destination of the intrinsic coagulation pathway is to provide the propagation of clotting. Biochemical Society Transactions, 2000, 28, A328-A328.	3.4	0

#	ARTICLE	IF	CITATIONS
55	Mo-W10:5 Mechanisms of spatial clot growth on oxidized low density lipoprotein (OXLDL)-treated vascular cells as a model of atherothrombosis. Atherosclerosis Supplements, 2006, 7, 29.	1.2	0
56	Clotting Factor (Cf) Product Use And Same-Day Risk For Thrombotic Adverse Events (Tes), As Recorded In Large Health Care Database During 2008-2013 Study Period. Value in Health, 2014, 17, A473.	0.3	0
57	Inhibitory Effect of an Anti-Factor VIII Antibody Fragment On Factor VIII Activity in Different Functional Assays. Blood, 2012, 120, 4387-4387.	1.4	0
58	Thrombin Generation Responses to Human Factor Xla in Plasma of Animal Species. Blood, 2012, 120, 5142-5142.	1.4	0
59	Structural and Functional Characterization of a Codon Optimized Coagulation Factor VIII. Blood, 2016, 128, 3765-3765.	1.4	0
60	Characterization of Interaction of Factor VIII with Engineered Variants of a Single-Chain Variable Antibody Fragment. Blood, 2018, 132, 1170-1170.	1.4	0
61	Characterization of Protein Unable to Bind Von Willebrand Factor in Recombinant Factor VIII Products: Can We Reduce Their Immunogenicity?. Blood, 2020, 136, 25-26.	1.4	0